Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.4 , No. 3, Publication Date: Jul. 5, 2017, Page: 10-14
. The MDS-UPDRS) part III and the Non-Motor Symptoms Scale were applied to all the participants. Also, PDQ-8 and MDS-UPDRS parts IB and II were completed by the patients. A total of 198 patients were included. No statistically significant difference was found in the motor evaluation. Health-related quality of life and motor experiences of daily living were significantly better in the group receiving the brand-name pramipexole. In conclusion, Subjects with Parkinson’s disease treated with generic pramipexole scored worst in the self-reported motor experiences of daily living and quality of life.&picture=http://www.aascit.org/aascit/decorators/img/journal/922.jpg)
| [1] | Ned Merari Dávila-Avila, Neurodegenerative Disease Clinical Research Unit, National Institute of Neurology and Neurosurgery, Mexico City, Mexico. |
| [2] | Mayela Rodríguez-Violante, Neurodegenerative Disease Clinical Research Unit, National Institute of Neurology and Neurosurgery, Mexico City, Mexico; Movement Disorder Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico. |
| [3] | Kenia Arredondo-Blanco, Neurodegenerative Disease Clinical Research Unit, National Institute of Neurology and Neurosurgery, Mexico City, Mexico. |
| [4] | Amin Cervantes-Arriaga, Neurodegenerative Disease Clinical Research Unit, National Institute of Neurology and Neurosurgery, Mexico City, Mexico. |
Generic drugs are widely considered to be cost-efficient substitutes for brand-name medications. The objective of this study is to compare patient-reported outcomes and investigator-rated outcomes in patients with PD treated with generic versus brand-name immediate-release pramipexole. For this purpose, a cross-sectional study was carried out. Patients on a stable dose of immediate-release pramipexole were divided in two groups (brand-name and generic drug). The MDS-UPDRS) part III and the Non-Motor Symptoms Scale were applied to all the participants. Also, PDQ-8 and MDS-UPDRS parts IB and II were completed by the patients. A total of 198 patients were included. No statistically significant difference was found in the motor evaluation. Health-related quality of life and motor experiences of daily living were significantly better in the group receiving the brand-name pramipexole. In conclusion, Subjects with Parkinson’s disease treated with generic pramipexole scored worst in the self-reported motor experiences of daily living and quality of life.
Keywords
Parkinson’s Disease, Patient-Reported, Pramipexole, Generic, Brand
Reference
| [01] | de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006; 5(6): 525-535. doi: 10.1016/S1474-4422(06)70471-9 |
| [02] | Alonso Cánovas A, Luquin Piudo R, García Ruiz-Espiga P, et al. Dopaminergic agonists in Parkinson’s disease. Neurologia 2014; 29(4): 230-241. doi: 10.1016/j.nrl.2011.04.012 |
| [03] | Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009; 43(10):1583-1597. doi: 10.1345/aph.1M141 |
| [04] | Rathe JØ. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting. Dan Med J. 2015 Oct; 62(10): B5148. |
| [05] | Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA 1994; 271(20): 1609-1614. |
| [06] | Enserink M. Can the placebo be the cure? Science 1999; 284(5412): 238-240. |
| [07] | Freeman TB, Vawter DE, Leaverton PE, et al. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson’s disease. N Eng J Med 1999; 341(13): 988-992. doi: 10.1056/NEJM199909233411311 |
| [08] | Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: A new era in clinical research. Perspect Clin Res 2011; 2(4): 137–144. doi: 10.4103/2229-3485.86879 |
| [09] | Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55(3): 181-184. |
| [10] | Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010; 25(15): 2649-2653. doi: 10.1002/mds.23429 |
| [11] | Silva-Arciniega MR, Brain-Calderón ML. Construcción de un instrumento de medición. In: Silva-Arciniega MR, Brain-Calderón ML, editors. Validez y confiabilidad del estudio socioeconómico. México: Universidad Nacional Autónoma de México; 2006. p 63–68. |
| [12] | Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, et al. Expanded and independent validation of the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). J Neurol 2013; 260(1): 228-236. doi: 10.1007/s00415-012-6624-1 |
| [13] | Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1998; 50(2):318. |
| [14] | Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire. Psychol Health 1997;12(6): 805–814. doi: 10.1080/08870449708406741 |
| [15] | Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Results from an international pilot study. Mov Disord 2007;22(13): 1901-1911. doi: 10.1002/mds.21596 |
| [16] | Pahwa RPR, Lyons KE, Majama J, et al. Clinical experience with generic carbidopa levodopa (GeL) in patients with Parkinson’s disease (PD). Neurology 1994; 44:A244. |
| [17] | Pahwa R, Marjama J, McGuire D, et al. Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. Mov Disord 1996; 11(4):27-430. doi: 10.1002/mds.870110412 |
| [18] | Gasser UE, Fischer A, Timmermans JP, Arnet I. Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar/Prolopa. BMC Pharmacol Toxicol 2013; 14:24. doi: 10.1186/2050-6511-14-24 |
| [19] | Chaná P, Fierro A, Reyes-Parada M, Sáez-Briones P. Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson's disease: a single dose study. Rev Med. Chile 2003; 131(6): 623-631. |
| [20] | Bosnyák E, Herceg M, Pál E, et al. Are Branded and Generic Extended-Release Ropinirole Formulations Equally Efficacious? A Rater-Blinded, Switch-Over, Multicenter Study arkinsons Dis. 2014; 2014:158353. doi: 10.1155/2014/158353 |
| [21] | Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical and ethical advances of placebo effetcs. Lancet 2010; 375(9715):686-695. doi: 10.1016/S0140-6736(09)61706-2 |
| [22] | Espay AJ, Norris MM, Eliassen JC, et al. Placebo effect of medication cost in Parkinson disease. Neurology 2015; 84(8):1-9. doi: 10.1212/WNL.0000000000001282 |
| [23] | Van der Meersch A, Dechartres A, Ravaud P. Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review. PLoS ONE 2011; 6(8):e23611. doi: 10.1371/journal.pone.0023611 |
| [24] | Go CL, Rosales RL, Schmidt P, Lyons KE, Pahwa R, Okun MS. Generic versus branded pharmacotherapy in Parkinson's disease: does it matter? A review. Parkinsonism Relat Disord 2011; 17:308-312. doi: 10.1016/j.parkreldis.2011.02.005 |
| [25] | Horváth K, Aschermann Z, Ács P, et al. Minimal clinically important difference on the motor examination part of MDS-UPDRS. Parkinsonism Relat Disord 2015; 21:1421-1426. doi: 10.1016/j.parkreldis.2015.10.006 |
